Clinical Trial Update: Study of BPZE1 (High Dose) Nasal Live Attenuated B. Pertussis Vaccine [Phase 1]

View source ↗

Summary

Phase 1 study of BPZE1, a high-dose nasal live attenuated vaccine against pertussis, has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pertussis

Drugs mentioned

• BPZE1 (Bordetella pertussis live attenuated vaccine BPZE1)

Snippet

Sponsor: Institut National de la Santé Et de la Recherche Médicale, France | Conditions: Pertussis, Whooping Cough | Phase 1 | Status: COMPLETED | Results posted: 2020-01-02